Get started
Author

Philip Bejon

Observed names: Bejon, Philip, P. Bejon, Philippe Bejon
Observed institutions: Churchill Hospital, Kenya Medical Research Institute, University of Oxford, University Hospital of Geneva, KEMRI-Wellcome Trust Research Programme, Wellcome Trust
ORCID: 0000-0002-2135-7549
Observed ORCID: 0000-0002-2135-7549
OpenAlex ID: A5112747566
Taking social relationships seriously: Lessons learned from the informed consent practices of a vaccine trial on the Kenyan Coast
2008 · Caroline Gikonyo, Philip Bejon, et al. · Social Science & Medicine · 170
PDF
Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
2017 · Anne Rechtien, Laura Richert, et al. · Cell Reports · 124
PDF
Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection
2014 · Susanne H. Hodgson, Elizabeth Juma, et al. · Frontiers in Microbiology · 115
PDF
Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization
2017 · Christine Dahlke, Rahel Kasonta, et al. · EBioMedicine · 78
PDF
Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants
2016 · Muhammed O Afolabi, Alfred B Tiono, et al. · Molecular Therapy · 63
PDF
Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations
2014 · Domtila Kimani, Ya Jankey Jagne, et al. · Molecular Therapy · 54
Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care
2011 · Johan Vekemans, Kevin Marsh, et al. · Malaria Journal · 32
PDF
Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability
2023 · Angela Huttner, Selidji Todagbe Agnandji, et al. · Clinical Microbiology and Infection · 25
PDF
Detection of low frequency artemisinin resistance mutations, C469Y, P553L and A675V, and fixed antifolate resistance mutations in asymptomatic primary school children in Kenya
2025 · Victor Osoti, Kevin Wamae, et al. · BMC Infectious Diseases · 19
PDF
Understanding the benefits and burdens associated with a malaria human infection study in Kenya: experiences of study volunteers and other stakeholders
2021 · Primus Che Chi, Esther Awuor Owino, et al. · Trials · 19
PDF
Third human challenge trial conference, Oxford, United Kingdom, February 6–7, 2020, a meeting report
2020 · Andrew J. Pollard, Robert Sauerwein, et al. · Biologicals · 19
Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya
2024 · Doreen Lugano, Bernadette Kutima, et al. · BMC Infectious Diseases · 11
PDF
Malaria vaccines: past, present and future
2013 · Lorenz von Seidlein, Philip Bejon · Archives of Disease in Childhood · 11
Impact of introducing RTS,S/AS01E malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme
2026 · Victor Mwapasa, Kwaku Poku Asante, et al. · The Lancet · 8
Serial cross-sectional school surveys identifies C469Y, P553L, R561H and A675V kelch 13 mutations associated with artemisinin resistance in Western Kenya
2025 · Victor Osoti, Kevin Wamae, et al. · Scientific Reports · 8
PDF
Symptom prevalence and secondary attack rate of SARS‐CoV‐2 in rural Kenyan households: A prospective cohort study
2023 · Katherine E. Gallagher, Joyce Nyiro, et al. · Influenza and Other Respiratory Viruses · 7
PDF
Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial
2026 · Derick Kimathi, Aitana Juan-Giner, et al. · The Lancet · 6
Longitudinal Epidemiology and Variant Dynamics of SARS-CoV-2 in Coastal Kenya (2020–2025): Clinical Features and Wave Patterns
2026 · Arnold W Lambisia, Joyce Nyiro, et al. · Open Forum Infectious Diseases · 4
Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial
2026 · Melissa C. Kapulu, Francesca Orenge, et al. · Nature Medicine · 4
B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings
2026 · Caroline K Bundi, Olivia Muñoz, et al. · Frontiers in Immunology · 3
PDF
A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine
2014 · Michael T White, Philip Bejon, et al. · BMC Medicine · 3
PDF
Analysis of Immunity to Febrile Malaria in Children That Distinguishes Immunity from Lack of Exposure
2011 · Philip Bejon, George Warimwe, et al. · Infection and Immunity · 3
Emergence and transmission dynamics of the FY.4 Omicron variant in Kenya
2025 · Sebastian Musundi, Mike Mwanga, et al. · Virus Evolution · 2
PDF
Linking Cerebral Malaria Pathogenesis to APOE-Mediated Amyloidosis: Observations and Hypothesis
2024 · Mwikali Kioko, Shaban Mwangi, et al. · Molecular Neurobiology · 2
PDF
Cumulative Plasmodium falciparum infections do not drive long-term telomere shortening in Kenyan children
2026 · Aurelie Miglar, David Amadi, et al. · Frontiers in Cellular and Infection Microbiology · 1
PDF
Works count: 59
Citation count: 821
H-index: 12
I10-index: 14
Year
Topic
Type